FranklinMChuMDFACS

Urology • San Bernardino, CA

Stone Disease, Surgical Oncology

President, San Bernardino Urological associates Medical Group Inc, Medical Director, San Bernardino Urology Research Center

Join to view full profile

Dr. Chu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chu's full profile

Already have an account?

Office
489e 21st St
San Bernardino, CA 92404
Phone+1 909-882-2973

Fax+1 909-882-2681

Education & Training

University of California (Irvine)Residency, Urology, 1980 - 1985
University of Texas Medical Branch HospitalsInternship, Transitional Year, 1979 - 1980
Tulane University School of MedicineClass of 1979
University of Illinois at Urbana-ChampaignMS, Physical Chemitry, 1973 - 1974

Certifications & Licensure

OR State Medical License 1981 - Present
CA State Medical License 1981 - 2026
LA State Medical License 1979 - 1985
American Board of Urology Urology

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons

Clinical Trials

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Start of enrollment: 2003 Apr 01
Completed
Phase 4
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Start of enrollment: 2006 Apr 24
Completed
Phase 3
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2013 Oct 14
Active, not recruiting
Phase 3
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC Start of enrollment: 2015 Nov 27
Active, not recruiting
Phase 3
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Start of enrollment: 2017 Jun 13
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

15 citations
Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer
Evan Y. Yu, Robert H. Getzenberg, Christopher C. Coss, Marc M. Gittelman, Thomas E. Keane
European Urology. 2015-02-01
12 citations
A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate- resis...
Franklin Chu, Oliver Sartor, Leonard G. Gomella, Todd Rudo, Matthew C. Somerville
European Journal of Cancer. 2015-08-01
12 citations
Polymer‐delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open‐label studies in patients with...
Neal D. Shore, Franklin Chu, Judd W. Moul, Daniel Saltzstein, Raoul S. Concepcion
BJU International. 2017-02-01

Press Mentions

Linkin Park T-shirts Are All the Rage in ChinaJuly 9th, 2020
Clinical Investigation Site Summary: San Bernardino Urological Associates Treating Metastatic Castration Resistant Prostate CancerNovember 14th, 2019

Professional Memberships

American Urological Association - AUA
Member
American College of Surgeons - ACS
Member